WSJ -- Four years after launching the nonprescription diet pill Alli with much fanfare and a heavy marketing budget, U.K. drug maker GlaxoSmithKline PLC on Thursday said that it plans to sell off the drug along with a clutch of other over-the-counter brands. Glaxo once tipped Alli as a possible blockbuster, but sales never took off, and the drug was hurt last year by reports that a small number of people taking it experienced liver damage.
